Clinical trials recruiting for Hormone Receptor Positive HER-2 Negative Breast Cancer
8
Recruiting trials
20
US states with sites
16
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Abemaciclib | 3 |
| Fulvestrant | 3 |
| Elacestrant | 2 |
| Alisertib | 1 |
| Anti-Diarrheal Agent | 1 |
| BGB-43395 | 1 |
| Carboplatin | 1 |
| Cyclophosphamide | 1 |
| Docetaxel | 1 |
| EP0062 | 1 |
| Endocrine therapy | 1 |
| Epirubicin | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 3 |
| Massachusetts | 3 |
| Tennessee | 3 |
| Texas | 3 |
| Colorado | 2 |
| Connecticut | 2 |
| Michigan | 2 |
| Missouri | 2 |
| North Carolina | 2 |
| Ohio | 2 |
| Virginia | 2 |
| Alabama | 1 |
Top cities
Boston, Massachusetts 3Nashville, Tennessee 3Columbus, Ohio 2Dallas, Texas 2Detroit, Michigan 2New Haven, Connecticut 2St Louis, Missouri 2Tampa, Florida 2Atlanta, Georgia 1Aurora, Colorado 1
Self-screener
Recruiting trials
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
- Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- VS-6766+Abema+Fulv in Met HR+/HER- BC
Related conditions
Trials recruiting for Hormone Receptor Positive HER-2 Negative Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Hormone Receptor Positive Breast Cancer 24Metastatic breast cancer 131Hormone Receptor Positive Breast Carcinoma 13Recurrent Breast Cancer 4HR-positive, HER2-negative Advanced Breast Cancer 5HR+/HER2- Breast Cancer 17HER2-negative Breast Cancer 57CDK4/6 Inhibitor 4Breast Tumors 4
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Hormone Receptor Positive HER-2 Negative Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.